Elan (ELN) shares jump +4.6% premarket after Acorda Therapeutics (ACOR) announces positive...

|About: Elan Corporation, plc (ELN)|By:, SA News Editor

Elan (ELN) shares jump +4.6% premarket after Acorda Therapeutics (ACOR) announces positive prescriber response for its AMPYRA treatment for MS patients. The drug is manufactured by Elan in a supply agreement with Acorda.